Fundamental Analysis of Medpace Holdings Inc - Growth / Value Index
MEDP - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.0198
Price to Book Ratio of 25.62 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 39.30 | 45.03 | -15.06 % | |
Price to Book | 25.17 | 22.01 | -34.63 % | 18.41 |
Price to Sales | 6.26 | 6.90 | -22.50 % | |
Enterprise Value to EBITDA Multiple | 11.72 | 41.38 | -3.22 % |
MEDP - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 68.75
Piotroski F Score - Good Value of 7.0
Tremendous increasing trend in Net Profit for last 3 year
Excellent QoQ /QoQ FY EPS growth
Strong Return On Capital Employed of 48.87
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 64.05%
During the past twelve months, the company has given a strong Return On Asset of 20.18%
All key Trailing Twelve Months Margin growing by 15 %
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Net Margin in range of 15 to 20 for last 3 years
Steady Growth in EPS for last four quarters
Good Net Margin of 15.92% is achieved by the company
Very Low Dividend Yield of 0 %
Low Earning Yield of 2.50 %
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 64.05 | 48.87 | -23.04 % | 15.28 |
Return On Asset | 20.18 | 16.49 | -9.11 % | 5.71 |
Net Profit Margin | 15.92 | 15.33 | -8.76 % | 20.07 |
Operating Profit Margin | 17.87 | 18.30 | -4.16 % | 20.36 |
EBITDA Margin | 52.25 | 16.75 | -19.75 % | 56.43 |
Highlights
Market Cap | 11970.13 M |
Enterprise Value | 12017.64 M |
Price/Book TTM | 25.17 |
Outstanding Share | 30983.40 K |
Float/ Outstanding Share | 82.01% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 6.20 |
Peter Lynch Ratio | 0.451 |
Piotroski F Score | 7.00 |
Altman Z Score | 7.73 |
Sloan Ratio | -0.085 |
Peter Lynch Fair Value | 159.19 |
MEDP - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 1962.81 M | 22.02 % | 2.54 % |
Gross Profit | 549458 K | 16.42 % | 13.40 % |
EBITDA | 1025.60 M | 2.07 % | 12.28 % |
Net Profit | 312507 K | 11.34 % | 31.03 % |
EPS | 9.83 | 17.73 % | NA |
MEDP - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 65.62
Altman Z Score of 7.85 suggests good Stability
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.524 | 305.03 % | 0.406 |
Cash Ratio | 0.265 | 654.19 % | |
Quick Ratio | 0.642 | 0 % | 0.779 |
Shareholders Equity | 33.74 | 18.09 % | |
Debt to EBITDA | 0.982 | 498.32 % |
Historical Valuation Ratios of Medpace Holdings Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Medpace Holdings Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Medpace Holdings Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Medpace Holdings Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)